Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 14/20 | 0.47 |
| ▸ | AHR | P35869 | 2/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | MELK | Q14680 | 1/20 | 0.40 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30016027 | 1.00 | CHEK1 (0.47) | CHEK1AHRCYP2A6NR4A2JAK2 | |
| SCHEMBL22093860 | 0.83 | JAK2 (0.44) | CHEK1AHRJAK2RPS6KA3MELK | |
| SCHEMBL25151016 | 0.82 | CHEK1 (0.46) | CHEK1AHRCYP2A6NR4A2JAK2 | |
| SCHEMBL25151113 | 0.79 | CHEK1 (0.47) | CHEK1AHRCYP2A6NR4A2JAK2 | |
| SCHEMBL13139330 | 0.79 | CHEK1 (0.40) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL29026813 | 0.78 | CHEK1 (0.43) | CHEK1AHRCYP2A6NR4A2JAK2 | |
| SCHEMBL25073866 | 0.76 | CHEK1 (0.43) | CHEK1AHRJAK2RPS6KA3MELK | |
| SCHEMBL30279145 | 0.76 | CHEK1 (0.43) | CHEK1AHRJAK2RPS6KA3MELK | |
| SCHEMBL25317975 | 0.75 | CHEK1 (0.42) | CHEK1JAK2RPS6KA3MELKSTK24 | |
| SCHEMBL31204349 | 0.75 | CHEK1 (0.43) | CHEK1AHRCYP2A6NR4A2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250332173-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20240425479-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-12-26 | — | — | US | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| EP-4416141-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | Remix Therapeutics Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| EP-4330246-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | Ontario Institute for Cancer Research (OICR) (CA) | 2024-03-06 | — | — | EP | disclosed |
| CN-117597336-A | Halogen substituted amino aza-heteroaryl compounds as inhibitors of hematopoietic progenitor kinase 1 (HPK 1) | 安大略省癌症研究所(OICR) | 2024-02-23 | — | — | CN | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023064880-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064880-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20220411404-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| WO-2022226665-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
| EP-3917911-A1 | 15-PGDH INHIBITORS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160151-A1 | 15-PGDH INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2020-08-06 | — | — | WO | disclosed |
| WO-2004072101-A2 | PHENYLGLYCINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332173-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, NSUN2, SNRPA1 | CHEK1 2011/4885AHR 4576/4885CYP2A6 4333/4885 |
| US-20220411404-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | CHEK1 170/4885AHR 2365/4885CYP2A6 4421/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | CHEK1 59/4885AHR 2502/4885CYP2A6 3290/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | CHEK1 59/4885AHR 2502/4885CYP2A6 3290/4885 |
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | CHEK1 158/4885AHR 944/4885CYP2A6 2348/4885 |
| US-20240425479-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | DCK, CMPK1, WNK1 | CHEK1 220/4885AHR 1105/4885CYP2A6 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.